towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma
towards improved death receptor targeted therapy for ... - TI Pharma
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chapter 5<br />
targets and subsequent proteasomal degradation thus removing possible anti‐apoptotic<br />
proteins resulting in sensitization <strong>for</strong> apoptosis [15]. The small molecule, 17‐allylamino‐17‐<br />
demethoxy‐geldanamycin (17‐AAG) is a potent Hsp90 inhibitor that induces cell cycle<br />
arrest and apoptosis in a variety of tumor cells, including NSCLC [16].<br />
In this study we investigated whether 17‐AAG enhances the apoptosis‐inducing effect of<br />
TRAIL in NSCLC cells. Furthermore, the mode of action of the synergy of these two<br />
compounds was studied.<br />
MATERIALS & METHODS<br />
Cell lines and reagents<br />
The NSCLC cell lines, A549 and H460, were cultured in RPMI‐1640 supplemented with 10%<br />
Fetal Calf Serum (FCS). The cells were maintained in a humidified incubator at 37 °C and in<br />
a 5% CO2‐atmosphere. TRAIL (PeproTech EC Ltd, London, UK) was aliquoted in PBS at a<br />
final concentration of 500 ng/ml and stored at ‐20 °C. 17‐AAG was diluted in DMSO (stock<br />
solution of 1mM) and stored at ‐20 °C. The caspase inhibitors Z‐VAD‐fmk (general caspase<br />
inhibitor), Z‐IETD‐fmk (caspase‐8) and Z‐LEHD‐fmk (caspase‐9) were purchased from<br />
Bachem AG, dissolved in DMSO (10 mM or 20 mM) and stored at ‐20 °C.<br />
Drug cytotoxicity assays<br />
Drug cytotoxicity was determined using the methyl thiazole tetrazolium (MTT) assay. Cells<br />
were seeded in 96‐wells plates with a cell density of 9,000 cells/well. After 24 h, enabling<br />
attachment, cells were exposed (in triplicate) to increasing concentrations of the two<br />
drugs <strong>for</strong> 24 h. Next, the medium was removed and 50 µl MTT (10% diluted in HBSS<br />
buffer) per well was added and incubated <strong>for</strong> 1‐3 h at 37 °C. After the incubation, 150 μl<br />
DMSO per well was added and following 10‐15 min slowly shaking, the absorbance of the<br />
plate was measured at 540 nm with a TECAN plate reader by using the XFLUOR4 program.<br />
IC50 values were determined from the graphs. Synergy of TRAIL and 17‐AAG was<br />
determined by calculation of the combination index (CI) using Calcusyn (Calcusyn Biosoft,<br />
Cambridge, UK) as described earlier [17]. For calculation of the CI, only values above a<br />
fraction affected (FA) of 0.5 were used, equivalent to 50 ‐ 100% growth inhibition. A CI <<br />
0.9 indicates synergism and >1.1 antagonism.<br />
Cell cycle and cell <strong>death</strong> measurements<br />
Cells were plated at a density of 200,000 cells/well in 6‐wells plates. After 24 h enabling<br />
attachment, the medium was replaced by medium containing the drug(s) as indicated.<br />
When indicated, caspase inhibitors were added to a final concentration of 20 µM, 2 h<br />
prior to drug treatment. After drug exposure cells were trypsinized, resuspended in<br />
medium collected from the matching sample and centrifuged <strong>for</strong> 5 min at 1200 rpm. After<br />
‐ 86 ‐